http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 17:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Amneal+Pharmaceuticals%2C+++For%3A+Jun+18/26667080.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260618/A42FN62CZM22CZKK222C2Z42I3QSZC22Z282">http://archive.fast-edgar.com/20260618/A42FN62CZM22CZKK222C2Z42I3QSZC22Z282</a></p> <p> Filed on: June 18, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Amneal+Pharmaceuticals%2C+++For%3A+Jun+18/26667080.html Thu, 18 Jun 2026 17:01:00 -0400 AMRX O.38058252 http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Amneal+Pharmaceuticals%2C+++For%3A+Jun+18/26667080.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260618/A42FN62CZM22CZKK222C2Z42I3QSZC22Z282">http://archive.fast-edgar.com/20260618/A42FN62CZM22CZKK222C2Z42I3QSZC22Z282</a></p> <p> Filed on: June 18, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++PREM14A++++Amneal+Pharmaceuticals%2C+++For%3A+Jun+18/26667080.html Thu, 18 Jun 2026 17:01:00 -0400 AMRX O.38058252 http://www.streetinsider.com/Press+Releases/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html <div class="xn-content"> <p><b>Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide</b></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- Dispensary of Hope announced the launch of its national <b>"<span>Hope Alliance</span>"</b> campaign this year, a strategic initiative designed to expand access to high-quality, longer-dated medications for low-income and uninsured patients across <location value="LC/us" idsrc="xmltag.org" >the United States</location>. One of the first manufacturers to commit its support of this effort is <b><span value="NASDAQ-NMS:AMRX" idsrc="xmltag.org" >Amneal Pharmaceuticals, Inc.</span> (Amneal)</b>, which has made a significant new commitment to the campaign's planned giving model to help http://www.streetinsider.com/Press+Releases/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html Wed, 10 Jun 2026 10:09:00 -0400 AMRX O.38058252 http://www.streetinsider.com/Press+Releases/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html <div class="xn-content"> <p><b>Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide</b></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- Dispensary of Hope announced the launch of its national <b>"<span>Hope Alliance</span>"</b> campaign this year, a strategic initiative designed to expand access to high-quality, longer-dated medications for low-income and uninsured patients across <location value="LC/us" idsrc="xmltag.org" >the United States</location>. One of the first manufacturers to commit its support of this effort is <b><span value="NASDAQ-NMS:AMRX" idsrc="xmltag.org" >Amneal Pharmaceuticals, Inc.</span> (Amneal)</b>, which has made a significant new commitment to the campaign's planned giving model to help http://www.streetinsider.com/Press+Releases/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html Wed, 10 Jun 2026 10:09:00 -0400 AMRX O.38058252 http://www.streetinsider.com/PRNewswire/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html <div class="xn-content"> <p><b>Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide</b></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- Dispensary of Hope announced the launch of its national <b>"<span>Hope Alliance</span>"</b> campaign this year, a strategic initiative designed to expand access to high-quality, longer-dated medications for low-income and uninsured patients across <location value="LC/us" idsrc="xmltag.org" >the United States</location>. One of the first manufacturers to commit its support of this effort is <b><span value="NASDAQ-NMS:AMRX" idsrc="xmltag.org" >Amneal Pharmaceuticals, Inc.</span> (Amneal)</b>, which has made a significant new commitment to the campaign's planned giving model to help http://www.streetinsider.com/PRNewswire/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html Wed, 10 Jun 2026 10:09:00 -0400 AMRX O.38058252 http://www.streetinsider.com/PRNewswire/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html <div class="xn-content"> <p><b>Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide</b></p><p><span class="legendSpanClass"><location value="LU/us.tn.nashvl" idsrc="xmltag.org" >NASHVILLE, Tenn.</location></span>, <span class="legendSpanClass"><chron>June 10, 2026</chron></span> /PRNewswire/ -- Dispensary of Hope announced the launch of its national <b>"<span>Hope Alliance</span>"</b> campaign this year, a strategic initiative designed to expand access to high-quality, longer-dated medications for low-income and uninsured patients across <location value="LC/us" idsrc="xmltag.org" >the United States</location>. One of the first manufacturers to commit its support of this effort is <b><span value="NASDAQ-NMS:AMRX" idsrc="xmltag.org" >Amneal Pharmaceuticals, Inc.</span> (Amneal)</b>, which has made a significant new commitment to the campaign's planned giving model to help http://www.streetinsider.com/PRNewswire/Dispensary+of+Hope+Launches+%26quot%3BHope+Alliance%26quot%3B+Campaign+with+Support+from+Amneal+Pharmaceuticals/26628168.html Wed, 10 Jun 2026 10:09:00 -0400 AMRX O.38058252 http://www.streetinsider.com/Corporate+News/Amneal+reports+positive+interim+results+for+Parkinson%27s+drug+CREXONT/26608494.html <p>Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) announced interim results from its Phase 4 ELEVATE-PD study showing clinical benefits for patients with Parkinson's disease who switched to CREXONT, the company's extended-release carbidopa and levodopa treatment.</p><p>The study evaluated 214 patients after six weeks of treatment. Patients who switched from immediate-release carbidopa/levodopa gained 3.33 hours of additional daily "Good On" time and reduced "Off" time by 3.20 hours. Those switching from immediate-release carbidopa/levodopa plus a COMT inhibitor gained 3.20 hours of "Good On" time and reduced "Off" time by 2.96 hours.</p><p>Patients switching from RYTARY, a competing extended-release treatment, gained 3.03 hours of daily "Good http://www.streetinsider.com/Corporate+News/Amneal+reports+positive+interim+results+for+Parkinson%27s+drug+CREXONT/26608494.html Fri, 05 Jun 2026 08:00:48 -0400 AMRX http://www.streetinsider.com/FDA/Amneal+reports+positive+interim+results+for+Parkinson%27s+drug+CREXONT/26608494.html <p>Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) announced interim results from its Phase 4 ELEVATE-PD study showing clinical benefits for patients with Parkinson's disease who switched to CREXONT, the company's extended-release carbidopa and levodopa treatment.</p><p>The study evaluated 214 patients after six weeks of treatment. Patients who switched from immediate-release carbidopa/levodopa gained 3.33 hours of additional daily "Good On" time and reduced "Off" time by 3.20 hours. Those switching from immediate-release carbidopa/levodopa plus a COMT inhibitor gained 3.20 hours of "Good On" time and reduced "Off" time by 2.96 hours.</p><p>Patients switching from RYTARY, a competing extended-release treatment, gained 3.03 hours of daily "Good http://www.streetinsider.com/FDA/Amneal+reports+positive+interim+results+for+Parkinson%27s+drug+CREXONT/26608494.html Fri, 05 Jun 2026 08:00:48 -0400 AMRX http://www.streetinsider.com/Corporate+News/Amneal+reports+positive+interim+results+for+CREXONT+in+Parkinson%27s+study/26608482.html <p>Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) announced interim results from its Phase 4 ELEVATE-PD study showing clinical benefits for patients with Parkinson's disease who switched to CREXONT, the company's extended-release carbidopa and levodopa capsules.</p><p>The study evaluated 214 patients after six weeks of treatment. Patients who switched from immediate-release carbidopa/levodopa gained 3.33 hours of daily "Good On" time, while those switching from RYTARY gained 3.03 hours. "Good On" time refers to periods when patients experience effective symptom control.</p><p>Patients switching from RYTARY showed additional improvements, with the duration of continuous "Good On" intervals nearly doubling from 3.19 hours at baseline to 6.27 hours http://www.streetinsider.com/Corporate+News/Amneal+reports+positive+interim+results+for+CREXONT+in+Parkinson%27s+study/26608482.html Fri, 05 Jun 2026 08:00:38 -0400 AMRX http://www.streetinsider.com/FDA/Amneal+reports+positive+interim+results+for+CREXONT+in+Parkinson%27s+study/26608482.html <p>Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) announced interim results from its Phase 4 ELEVATE-PD study showing clinical benefits for patients with Parkinson's disease who switched to CREXONT, the company's extended-release carbidopa and levodopa capsules.</p><p>The study evaluated 214 patients after six weeks of treatment. Patients who switched from immediate-release carbidopa/levodopa gained 3.33 hours of daily "Good On" time, while those switching from RYTARY gained 3.03 hours. "Good On" time refers to periods when patients experience effective symptom control.</p><p>Patients switching from RYTARY showed additional improvements, with the duration of continuous "Good On" intervals nearly doubling from 3.19 hours at baseline to 6.27 hours http://www.streetinsider.com/FDA/Amneal+reports+positive+interim+results+for+CREXONT+in+Parkinson%27s+study/26608482.html Fri, 05 Jun 2026 08:00:38 -0400 AMRX http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT^®</li><li style="text-align:left;">Patients switching to CREXONT^® from RYTARY^® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br /></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT^®</li><li style="text-align:left;">Patients switching to CREXONT^® from RYTARY^® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br /></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT^®</li><li style="text-align:left;">Patients switching to CREXONT^® from RYTARY^® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br /></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT^®</li><li style="text-align:left;">Patients switching to CREXONT^® from RYTARY^® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br /></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%27s+Disease/26608429.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT®</li><li style="text-align:left;">Patients switching to CREXONT® from RYTARY® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br/></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX O.38058252 http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT®</li><li style="text-align:left;">Patients switching to CREXONT® from RYTARY® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br/></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or http://www.streetinsider.com/Press+Releases/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX O.38058252 http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT®</li><li style="text-align:left;">Patients switching to CREXONT® from RYTARY® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br/></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX O.38058252 http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html <ul><li style="text-align:left;">Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups</li><li style="text-align:left;">Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful improvements in motor function were observed after switching to CREXONT®</li><li style="text-align:left;">Patients switching to CREXONT® from RYTARY® gained 3.03 hours of additional daily “Good On” time and nearly doubled the duration of continuous “Good On” intervals, enabling longer, uninterrupted periods of symptom control<br/></li></ul> <p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+Full+Study+Population+Interim+Phase+4+ELEVATE-PD+Results%2C+Reinforcing+Previously+Reported+Benefits+of+CREXONT%C2%AE+in+Parkinson%26apos%3Bs+Disease/26608443.html Fri, 05 Jun 2026 08:00:00 -0400 AMRX O.38058252 http://www.streetinsider.com/FDA/Amneal+receives+FDA+approval+for+romidepsin+injection+solution/26602730.html <p>Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) announced that the U.S. Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.</p> <p>The product received Competitive Generic Therapy designation, providing Amneal with 180 days of market exclusivity. The romidepsin injection solution references a former solution formulation previously marketed by Teva that was withdrawn from the market several years ago.</p> <p>Romidepsin injection solution is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma in adult patients who have received at least one prior systemic therapy. The ready-to-use formulation eliminates the need for reconstitution, unlike the http://www.streetinsider.com/FDA/Amneal+receives+FDA+approval+for+romidepsin+injection+solution/26602730.html Thu, 04 Jun 2026 08:00:53 -0400 AMRX http://www.streetinsider.com/Press+Releases/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html <ul><li><em>Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution</em></li><li><em>Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal’s differentiated injectables portfolio</em></li></ul> <p>BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.</p> <p>The product is eligible for Competitive Generic Therapy (CGT) designation, which provides Amneal with 180 days of market exclusivity. Since the FDA began tracking CGT http://www.streetinsider.com/Press+Releases/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html Thu, 04 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Press+Releases/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html <ul><li><em>Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution</em></li><li><em>Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal’s differentiated injectables portfolio</em></li></ul> <p>BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.</p> <p>The product is eligible for Competitive Generic Therapy (CGT) designation, which provides Amneal with 180 days of market exclusivity. Since the FDA began tracking CGT http://www.streetinsider.com/Press+Releases/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html Thu, 04 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html <ul><li><em>Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution</em></li><li><em>Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal’s differentiated injectables portfolio</em></li></ul> <p>BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.</p> <p>The product is eligible for Competitive Generic Therapy (CGT) designation, which provides Amneal with 180 days of market exclusivity. Since the FDA began tracking CGT http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html Thu, 04 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html <ul><li><em>Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution</em></li><li><em>Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal’s differentiated injectables portfolio</em></li></ul> <p>BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.</p> <p>The product is eligible for Competitive Generic Therapy (CGT) designation, which provides Amneal with 180 days of market exclusivity. Since the FDA began tracking CGT http://www.streetinsider.com/Globe+Newswire/Amneal+Announces+U.S.+FDA+Approval+of+Romidepsin+Injection+Solution/26602587.html Thu, 04 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Press+Releases/Amneal+to+Participate+in+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference+2026/26579385.html <p>BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47^th Annual Global Healthcare Conference 2026 being held on June 8-10 at the Loews Miami Beach Hotel in Miami, FL.</p> <p>A company presentation will take place on Tuesday June 9, 2026, at 8:40AM EDT. A live webcast of the presentation will be available <a href="https://www.globenewswire.com/Tracker?data=4E6sQyEYuTd3G8p9_Btw5ysadAEcYLYMxZHI9jaMPM0lUfgvDRgCeT1y-9WI3ug-gqu5v1m5lYB3PPSDCnm2Nj5Ix2vfbovpVrRmy6Q0nT30guiC0Zn6Q0F0Q7ppbMepnM5e07OE60aIFT1RHl9K3x_l_5sWibGCiBX48HzKkxk=" rel="nofollow" target="_blank">here</a>.</p> <p><strong>About Amneal</strong><br />Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global http://www.streetinsider.com/Press+Releases/Amneal+to+Participate+in+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference+2026/26579385.html Mon, 01 Jun 2026 08:00:00 -0400 AMRX AMRX http://www.streetinsider.com/Press+Releases/Amneal+to+Participate+in+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference+2026/26579385.html <p>BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47^th Annual Global Healthcare Conference 2026 being held on June 8-10 at the Loews Miami Beach Hotel in Miami, FL.</p> <p>A company presentation will take place on Tuesday June 9, 2026, at 8:40AM EDT. A live webcast of the presentation will be available <a href="https://www.globenewswire.com/Tracker?data=4E6sQyEYuTd3G8p9_Btw5ysadAEcYLYMxZHI9jaMPM0lUfgvDRgCeT1y-9WI3ug-gqu5v1m5lYB3PPSDCnm2Nj5Ix2vfbovpVrRmy6Q0nT30guiC0Zn6Q0F0Q7ppbMepnM5e07OE60aIFT1RHl9K3x_l_5sWibGCiBX48HzKkxk=" rel="nofollow" target="_blank">here</a>.</p> <p><strong>About Amneal</strong><br />Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global http://www.streetinsider.com/Press+Releases/Amneal+to+Participate+in+Goldman+Sachs+47th+Annual+Global+Healthcare+Conference+2026/26579385.html Mon, 01 Jun 2026 08:00:00 -0400 AMRX AMRX